3 recruiting, 1 withdrawn. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 3, Withdrawn 1 |
Follow Staphylococcus Aureus Endocarditis: new trials by email Literature Review of Staphylococcus Aureus Endocarditis trials Research Report on Staphylococcus Aureus Endocarditis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia Clopidogrel, Aspirin - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2026-02-23 | 2026-11-12 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Oritavancin for Staphylococcus Aureus Infections in Opioid Users Oritavancin Injection - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 4 | Withdrawn | University of Pennsylvania | 2019-07-01 | 2022-04-06 |
Aspirin (1) · Clopidogrel (1) · Dabigatran (1) · Daptomycin (1) · Injections (1) · Rivaroxaban (1) · Vancomycin (1) · apixaban (1) · edoxaban (1) · oritavancin (1)
Todd C. Lee MD MPH FIDSA (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Pennsylvania (1)
Canada (3) · Australia (1) · New Zealand (1) · United States (1)
Todd C Lee, MD MPH FIDSA (2) · Emily G McDonald, MD MSC (1) · Emily G McDonald, MD MSc (1) · Pablo Tebas, MD (1)
2025 (3)